Pathophysiology of Pain: Receptors, Pathways & Modulation

Complex Regional Pain Syndrome (CRPS) is a neuropathic pain condition characterized by long-lasting pain disproportionate to the underlying cause, typically following injury, fracture, or surgery; it involves multiple pathophysiological mechanisms including inflammatory changes (elevated pro-inflammatory cytokines and neuropeptides), immunological changes (autoantibodies against receptors), and pain sensitization (peripheral and central sensitization), presenting with regional pain, hyperalgesia, allodynia, erythema, edema, hyperhidrosis, and trophic changes, diagnosed using Budapest criteria requiring patient-reported symptoms across three of four domains plus clinical signs in two domains, and managed through prevention strategies (early mobilization, vitamin C supplementation, smoking cessation), physical therapy, pharmacotherapy (NSAIDs, topical capsaicin, bisphosphonates, gabapentin, amitriptyline), and advanced interventions like spinal cord stimulation.

Fibromyalgia is a specific small fiber neuropathy damaging the smallest nerves in skin and eyes, causing pain and autonomic dysfunction. Diagnosis uses skin biopsies or corneal microscopy to reveal nerve damage. Genetic studies show Mexican and Spanish patients have altered adrenaline-clearing enzymes and adrenergic receptor abnormalities. The fundamental pathophysiology involves constant sympathetic hyperactivity (excess adrenaline) from genetic predisposition or environmental stressors, triggering nerve damage and neuropathic pain. This excess adrenaline explains insomnia and fatigue, providing a comprehensive disease model.

Fibromyalgia is a complex syndrome characterized by widespread pain affecting connective and muscle tissues, derived from Greek roots meaning 'pain in fibrous and muscle tissues.' Beyond primary pain, patients commonly experience sleep disturbances, irritable bowel syndrome, restless legs, exercise intolerance, and mental health issues including depression and anxiety. Classified as an exclusion diagnosis, it is diagnosed only after ruling out other conditions, creating diagnostic uncertainty. Pain is fundamentally categorized into neuropathic pain (nerve damage) and nociceptive pain (tissue damage), but fibromyalgia represents an atypical condition where neither mechanism fully explains the pain. Research reveals immune system dysfunction involving immune globulins that trigger abnormal inflammatory responses when transferred to healthy organisms. Microscopic examination shows abnormal accumulations of glial cells—protective sheaths around nerve fibers—that become inflamed and lose their normal protective function, disrupting nerve signaling and contributing to chronic pain.

Neuropathic pain results from lesions affecting the somatosensory system, which can be central (spinal cord or brain), peripheral (nerves), or mixed, and involves complex mechanisms including peripheral sensitization (inflammatory mediators lowering pain thresholds, ectopic discharges from neuromas, and sympathetic nervous system involvement), central sensitization (glutamate-mediated amplification through NMDA receptor activation and calcium-dependent long-term potentiation), and impaired descending inhibitory modulation, leading to spontaneous pain, hyperalgesia, and allodynia that significantly impact patient quality of life.

Complex Regional Pain Syndrome (CRPS) is a chronic pain disorder characterized by persistent pain, swelling, and vasomotor instability in one or more body regions, typically triggered by surgery or trauma; it involves autonomic nervous system dysfunction and presents with hallmark symptoms including burning/stinging pain, hyperalgesia (increased pain sensitivity), allodynia (pain from non-painful stimuli), skin color changes, temperature abnormalities, and excessive sweating, diagnosed using the Budapest criteria which requires persistent pain disproportionate to injury plus symptoms across at least three of four categories (sensory, vasomotor, sudomotor, motor/trophic), with treatment involving multidisciplinary approaches including pain management, physical therapy, and psychological support.

Interventional approaches target pain at its source: nerve blocks using ultrasound/fluoroscopy guidance deliver local anesthetic and steroid to compressed nerves; sympathetic nerve blocks address sensitized sympathetic nervous system activity contributing to chronic pain; radiofrequency ablation (nerve burning at ~60°C) provides 6-12 months relief if repeat blocks are effective; and spinal cord stimulators offer adjustable electrical modulation for refractory cases. Success depends on accurate diagnosis and appropriate procedure selection.

This section covers interventional pain management techniques. Step 4 includes peripheral nerve blocks, spinal cord stimulation (implanting electrodes that deliver electrical impulses to modulate pain signals), and intrathecal drug delivery (implanting a pump that continuously infuses medication directly into the cerebrospinal fluid). Step 5 includes surgical interventions. The section explains that these techniques are used for refractory pain when pharmacological management is insufficient or causes unacceptable side effects.

Interventional approaches provide alternatives for patients failing pharmacologic therapy. Radiofrequency ablation uses heat to selectively destroy sensory nerves transmitting pain signals from affected joints, following diagnostic local anesthetic blocks. Spinal cord stimulation delivers electrical impulses to the epidural space, distracting the brain from pain signals. High-frequency stimulation (>10,000 Hz) achieves pain relief without producing sensation. These techniques offer targeted solutions for specific pain generators, particularly valuable for patients awaiting joint replacement or seeking improved postoperative outcomes.

Ideal candidates for interventional pain treatments must have pain distribution corresponding to identifiable nerve distributions, good response to diagnostic nerve injections with limited duration of relief, acceptance of the approach with understanding of risks and benefits, and no contraindications such as blood thinners (risk of dangerous bleeding around the spinal cord), active infections at injection sites, or technically impossible procedures. The Neuropathic Pain Special Interest Group of the Canadian Pain Society has published evidence-based guidelines for interventional pain treatments including spinal cord stimulation, intravenous infusions, epidural injections, and nerve blocks. These guidelines help physicians make informed decisions about when to use interventional techniques, ensuring treatments are helpful while avoiding procedures that may not provide benefit.

Complex Regional Pain Syndrome (CRPS) is a severe neuropathic pain condition that often doesn't respond well to standard treatments, requiring a multimodal approach that includes interventional pain management techniques such as sympathetic nerve blocks, epidural infusions, spinal cord stimulation, and ketamine infusions, all aimed at breaking the self-perpetuating cycle of peripheral and central sensitization, inflammation, and disuse atrophy that characterizes the condition.

The WHO analgesic ladder guides pain management: Step 1 (mild pain) uses non-opioids (paracetamol, NSAIDs); Step 2 (moderate pain) uses weak opioids (codeine, tramadol); Step 3 (severe pain) uses strong opioids (morphine preferred due to predictable pharmacokinetics). Adjuvant medications (antidepressants, gabapentinoids) can be used at any step. Oral route is preferred, but parenteral routes are used when oral intake is compromised. Cancer pain is complex, often involving multiple mechanisms simultaneously.

The World Health Organization recommends a three-step analgesic ladder for cancer pain management: Step 1 uses non-opioid analgesics like acetaminophen and dipirona; Step 2 adds weak opioids for moderate pain; Step 3 uses strong opioids for severe pain. Effective pain management requires multimodal analgesia combining drugs with different mechanisms of action at lower doses, avoiding monotherapy and always providing rescue medication for breakthrough pain.

The WHO three-step analgesic ladder provides a framework for cancer pain management: non-opioids for mild pain, weak opioids plus adjuvants for moderate pain, and strong opioids for severe pain. However, this should be used bidirectionally rather than strictly unidirectionally. Common myths include: morphine hastens death (actually improves survival with effective pain control), injectable morphine works better than oral (oral is preferred), and strong opioids should only be used near end-of-life (can be used for moderate pain with normal vitals). These misconceptions contribute to undertreatment of pain in palliative care settings.

Palliative care provides care to chronically or terminally ill patients, focusing on improving quality of life and managing symptoms (especially pain). Principles: Does not affect life expectancy; Does not provide cure; Does not prescribe euthanasia (especially in India). WHO analgesic ladder (1986): Step 1 - mild pain with non-opioids (aspirin, paracetamol, NSAIDs); Step 2 - moderate pain with weak opioids (codeine, oxycodone, tramadol) + adjuvants; Step 3 - severe pain with strong opioids (morphine, fentanyl) + adjuvants. Adjuvants include calcitonin/bisphosphonates for bone pain, gabapentin/antidepressants for neuropathic pain. Palliative care does not affect life expectancy, does not provide cure, and does not prescribe euthanasia.

Opioid overdose risk occurs when concentrations exceed therapeutic levels, with risk factors including history of substance abuse and concomitant CNS depressants. The WHO Analgesic Ladder (1986) provides a framework: Step 1 (non-opioids), Step 2 (weak opioids), Step 3 (strong opioids). A key difference is the ceiling effect: weak opioids have a maximum dose beyond which additional analgesia is not achieved but side effects increase. Tramadol requires careful management with slow IV infusion and caution in seizure risk. Morphine is the reference opioid due to extensive research, multiple administration routes, affordability, and availability. Morphine is the first-choice opioid for cancer pain with no standard dose; 10-30 mg every 4 hours is typical.